Picture [iito] Back into Ad 650x80px
Employment/Membership › Details

Sophia Genetics–Hashimoto L: management, 202004– CBO before Roche Diagnostics


Period Period 2020-04-01
Organisations Organisation Sophia Genetics S.A.
  Group Sophia Genetics (Group)
  Organisation 2 Roche Diagnostics (Group Division)
  Group Roche (Group)
Products Product Sophia DDM (Data Driven Medicine)
  Product 2 DNA sequencing technology
Person Person Hashimoto, Lara (Sophia Genetics 202004– CBO before Roche Diagnostics)

Sophia Genetics S.A.. (4/8/20). "Press Release: Sophia Genetics Expands its Executive Team, Naming Lara Hashimoto Chief Business Officer". Lausanne & Boston, MA.

SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Lara Hashimoto has joined its Executive Team as Chief Business Officer, effective April 1st. She will be responsible for Marketing, Product Management and Business Development.

Lara Hashimoto joined the healthcare industry 20 years ago holding several leadership roles spanning Pharma clinical drug development, sales and marketing before moving to Roche Diagnostics. Here, she held a number of roles responsible for IVD development and commercialization, including the launch of the Oncology companion diagnostics portfolio. Her most recent position before joining SOPHiA GENETICS was Chief Commercial Officer for Roche Sequencing Solutions.

“Lara is a stellar addition to our successful team. She shares the company’s vision regarding multi-modal data approaches and the optimization of drug development and has made it her mission to help improve patients’ lives. Lara will greatly further our efforts to democratize Data-Driven Medicine worldwide,” said Jurgi Camblong, Founder and CEO of SOPHiA GENETICS.

“I believe the future in healthcare will be increasingly individualized with significantly improved outcomes through the application of multi-modality prediction modelling,” said Hashimoto. “SOPHiA GENETICS is best positioned to drive this transformation.”


SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare disease management, the universal SOPHiA Platform allows clinical researchers to act with precision and confidence. The company’s innovative approach enables an ever-expanding community of over 1’000 institutions to benefit from knowledge sharing, fostering a new era in healthcare. SOPHiA’s achievement is recognized by the MIT Technology Review’s "50 Smartest Companies".

More info: SOPHiAGENETICS.COM, follow @SOPHiAGENETICS on Twitter.

Media contacts

Global Media Contact
Sophie Reymond
Tel: +41 79 784 63 76

USA Media Contact
Don Granese
Tel: +1 857-263-7972

Record changed: 2020-06-07


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Sophia Genetics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top